Stifel Upgrades Supernus Pharmaceuticals (SUPN) to Buy, Would be Buyer On Weakness
Tweet Send to a Friend
Stifel upgraded Supernus Pharmaceuticals (NASDAQ: SUPN) from Hold to Buy with a price target of $47.00.Analyst Annabel Samimy believes with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
